Explore All Access
Check if your research matches the topics covered in JTO Clinical and Research Reports?
- Degree of match
- Common matching concepts
- Additional journal recommendations
JTO Clinical and Research Reports : Impact Factor & More
eISSN: 2666-3643
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
JTO Clinical and Research Reports Key Metrics
CiteScore 
1
Time to Accept
3
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months39%
4 to 6 months45%
7 to 9 months13%
Above 9 months4%
Did you find this useful?
Topics Covered on JTO Clinical and Research Reports
Apoptosis protein
Lung cancer
Capmatinib
Immunotherapy
Erlotinib
Receptor tyrosine kinase inhibitor
Genome evolution
Metastatic Lung Adenocarcinoma
Osimertinib
Persistent Disease
Survival advantage
Progression-free survival
Epidermal Growth Factor Receptor Inhibitors
Pembrolizumab
Platinum
Acquired resistance
Therapeutic window
Mesothelioma
Systematic review
Afatinib
JTO Clinical and Research Reports Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | USD 2000 |
| Publication Time | 19 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | International Association for the Study of Lung Cancer |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in JTO Clinical and Research Reports ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JTO Clinical and Research Reports
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
- 1 Nov 2024
- JTO Clinical and Research Reports
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors
- 1 Nov 2024
- JTO Clinical and Research Reports
Corrigendum to ‘Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC’ [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659]
- 1 Nov 2024
- JTO Clinical and Research Reports
Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors
- 1 Nov 2024
- JTO Clinical and Research Reports
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?
- 1 Nov 2024
- JTO Clinical and Research Reports
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
- 1 Nov 2024
- JTO Clinical and Research Reports
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
- 1 Nov 2024
- JTO Clinical and Research Reports
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors
- 1 Nov 2024
- JTO Clinical and Research Reports
Corrigendum to ‘Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC’ [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659]
- 1 Nov 2024
- JTO Clinical and Research Reports
Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors
- 1 Nov 2024
- JTO Clinical and Research Reports
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?
- 1 Nov 2024
- JTO Clinical and Research Reports
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
- 1 Nov 2024
- JTO Clinical and Research Reports
Compare Similar Journals with JTO Clinical and Research Reports
Select Journals to Compare with JTO Clinical and Research Reports
Total journals - 10
You can select up to 3 Journals at a time
Journal of Thoracic Oncology
Publisher: ELSEVIER SCIENCE INC
Annals of Oncology
Publisher: ELSEVIER
Lung Cancer
Publisher: ELSEVIER IRELAND LTD
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Thoracic Cancer
Publisher: WILEY
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Clinical Lung Cancer
Publisher: CIG MEDIA GROUP, LP
TRANSLATIONAL LUNG CANCER RESEARCH
Publisher: AME PUBLISHING COMPANY
Medicine
Publisher: Elsevier
European Journal of Cancer
Publisher: ELSEVIER SCI LTD
0 Journals Selected to compare with
JTO Clinical and Research Reports
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on JTO Clinical and Research Reports
How many articles did JTO Clinical and Research Reports publish last year? 
In 2023, JTO Clinical and Research Reports publsihed 148 articles.
What is Citescore for JTO Clinical and Research Reports?
Citescore for JTO Clinical and Research Reports is 1.
Who is the publisher of JTO Clinical and Research Reports?
Elsevier is the publisher of JTO Clinical and Research Reports.
